Cell cycle arrest at G2/M, apoptosis induction, and reduced ERK activation levels were also observed in NSCLC cell lines (H2122, H358, H460) containing KRAS mutation in response to small molecule 0375–0604 treatment, a KRAS inhibitor according to docking studies [70]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.